View Older Stories View More Recent Stories

Jan 8, 2018 06:30AM FDA Accepts New Drug Applications for Merck’s Doravirine, the Company’s Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection
Jan 3, 2018 04:45PM Merck to Participate at the 36th Annual J.P. Morgan Healthcare Conference
Jan 3, 2018 06:45AM Merck to Hold Fourth-Quarter and Full-Year 2017 Sales and Earnings Conference Call on February 2
Jan 2, 2018 07:02AM Merck (MRK) Reports KEYTRUDA Approval in Japan for Use in Treatment of Patients with Urothelial Carcinoma That is Unresectable with Radical Surgery
Jan 2, 2018 07:00AM Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan for Use in the Treatment of Patients with Urothelial Carcinoma That is Unresectable with Radical Surgery Who Have Progressed Following Cancer Che
Dec 22, 2017 07:02AM Merck (MRK) and Pfizer (PFE) Announce FDA Approval of SGLT2 Inhibitor STEGLATRO and Fixed-Dose Combination STEGLUJAN for Adults with Type 2 Diabetes
Dec 22, 2017 07:00AM FDA Approves SGLT2 Inhibitor STEGLATRO™ (ertugliflozin) and Fixed-Dose Combination STEGLUJAN™ (ertugliflozin and sitagliptin) for Adults with Type 2 Diabetes
Dec 21, 2017 01:10PM Merck (MRK) and Pfizer (PFE) Granted FDA Breakthrough Therapy Designation for Avelumab, INLYTA Combo in Advanced Renal Cell Carcinom
Dec 21, 2017 01:07PM FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma
Dec 21, 2017 01:00PM FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma
Dec 14, 2017 04:47PM Merck (MRK) Provides Update on Phase 3 Study of KEYTRUDA in Previously Treated Patients with GEJ
Dec 14, 2017 04:45PM Merck Provides Update on KEYNOTE-061, a Phase 3 Study of KEYTRUDA® (pembrolizumab) in Previously Treated Patients with Gastric or Gastroesophageal Junction Adenocarcinoma
Dec 11, 2017 06:31AM Merck (MRK) Announces FDA Accepts sBLA, Assigns Priority Review to its KEYTRUDA for Treatment of Relapsed or Refractory PMBCL
Dec 11, 2017 06:30AM FDA Accepts Supplemental Biologics License Application (sBLA), Assigns Priority Review to Merck’s KEYTRUDA® (pembrolizumab) for Treatment of Relapsed or Refractory Primary Mediastinal Large B-Cell
Dec 6, 2017 05:04PM Merck (MRK) Announces NEJM Publishes Phase 3 Clinical Study of PREVYMIS, Its New CMV Prophylaxis Medicine
Dec 6, 2017 05:02PM New England Journal of Medicine Publishes Phase 3 Clinical Study of PREVYMIS™ (letermovir), Merck’s New CMV Prophylaxis Medicine
Nov 30, 2017 09:00AM Merck Commemorates 30 Years of MECTIZAN® Donation Program Progress
Nov 30, 2017 07:08AM Merck (MRK) Announces New, Updated Data for its KEYTRUDA and Updated Data on LYNPARZA in Multiple Breast Cancer Subtypes to Be Presented at SABCS
Nov 30, 2017 07:00AM New and Updated Data for Merck’s KEYTRUDA® (pembrolizumab) and Updated Data on LYNPARZA® (olaparib) in Multiple Breast Cancer Subtypes to Be Presented at the 2017 San Antonio Breast Cancer Symposi
Nov 29, 2017 07:00AM Impassioned Lung Cancer Survivors Join Your Cancer Game Plan, Merck to Advocate for Others Facing This Highly Stigmatized Disease
Nov 28, 2017 02:33PM Merck Announces Increased Quarterly Dividend and $10 Billion Share Repurchase Authorization
Nov 28, 2017 08:10AM Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Gastric 300 Study in Patients with Pre-Treated Advanced Gastric Cancer
Nov 28, 2017 08:04AM Merck (MRK) and Pfizer (PFE) Announce Phase III JAVELIN Gastric 300 Study in Patients With Pre-Treated Advanced Gastric Cancer Did Not Meet Primary Endpoint
Nov 28, 2017 08:00AM Merck and Pfizer Provide Update on Phase III JAVELIN Gastric 300 Study in Patients With Pre-Treated Advanced Gastric Cancer
Nov 14, 2017 06:55AM Merck Announces Final Results of Any and All Tender Offers
Nov 13, 2017 02:00PM Merck Announces Pricing of Any and All Tender Offers
Nov 13, 2017 10:10AM Trump taps ex-pharma executive Azar as U.S. health secretary
Nov 13, 2017 08:01AM Merck (MRK) Receives Positive CHMP Opinion for PREVYMIS in European Union
Nov 13, 2017 08:00AM Merck Receives Positive CHMP Opinion for PREVYMIS™ (letermovir) in the European Union
Nov 9, 2017 06:46AM Merck (MRK) Announces FDA Approval of PREVYMIS for Prevention of CMV Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients
Nov 9, 2017 06:45AM Merck Receives FDA Approval of PREVYMIS™ (letermovir) for Prevention of Cytomegalovirus (CMV) Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients
Nov 7, 2017 04:00AM Merck's Consumer Health Leads Debate on Preparing Gen Z for 100 Healthy Years
Nov 6, 2017 05:00PM Merck Animal Health Introduces Care & Control of Pet Diabetes To Help Pet Owners Deal with the Disease
Nov 6, 2017 08:56AM Merck Announces Any and All Tender Offers
Nov 2, 2017 09:00AM Merck Publishes Annual Corporate Responsibility Report
Nov 1, 2017 09:00AM Merck Animal Health Introduces Care & Control of Pet Diabetes To Help Pet Owners Deal with the Disease
Oct 27, 2017 04:18PM Merck (MRK) Withdraws European Application for KEYTRUDA in Combination with Pemetrexed and Carboplatin for First-Line Treatment of NSCLC
Oct 27, 2017 04:17PM Merck Provides Update on European Application for KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Carboplatin for First-Line Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
Oct 27, 2017 06:45AM Merck Announces Third-Quarter 2017 Financial Results
Oct 23, 2017 08:30PM Corning to Showcase Latest in Pharmaceutical Glass Technologies at CPhI Worldwide in Frankfurt, Germany
Oct 23, 2017 06:59AM Merck (MRK) & AstraZeneca PLC (AZN) Report Second Regulatory Submission to Rapidly Advance LYNPARZA (olaparib) in Japan
Oct 23, 2017 06:55AM AstraZeneca and Merck Rapidly Advance LYNPARZA® (olaparib) in Japan With a Second Regulatory Submission
Oct 23, 2017 05:47AM Merck (MRK) Announces Data from Real-World Study Shows ZEPATIER (Elbasvir and Grazoprevir)
Oct 21, 2017 02:00PM Real-World Study Shows ZEPATIER® (Elbasvir and Grazoprevir) Resulted in High Rates of Sustained Virologic Response in Patients with Chronic Hepatitis C Infection Who Have Chronic Kidney Disease
Oct 18, 2017 07:01AM Merck (MRK) and AstraZeneca (AZN) Granted FDA Acceptance of Regulatory Submission for LYNPARZA (Olaparib)
Oct 18, 2017 06:55AM U.S. FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in Metastatic Breast Cancer and Grants Priority Review
Oct 18, 2017 06:47AM Merck (MRK) Says KEYTRUDA More Than Doubled Median Overall Survival Compared to Chemotherapy After Two Years of Follow Up in First-Line Treatment of Patients with Metastatic NSCLC with High Levels of
Oct 18, 2017 06:45AM Merck’s KEYTRUDA® (pembrolizumab) More Than Doubled Median Overall Survival Compared to Chemotherapy After Two Years of Follow Up in First-Line Treatment of Patients with Metastatic Non-Small Cell
Oct 12, 2017 01:00PM Merck Makes $3 Million Charitable Donation to Support Swim Across America
Oct 12, 2017 06:55AM Merck Joins with the American Liver Foundation to Educate U.S. Veterans on Chronic Hepatitis C Virus (HCV) Infection
View More Recent Stories View Older Stories